Hyderabad (Telangana) [India], June 9 (ANI/PRNewswire): A2A Pharmaceuticals, a biotechnology company committed to the advancement of innovative scientific research and new therapeutic agents announces today an agreement to co-develop SARS-CoV-2 Main Proteases inhibitors for the treatment of